









Amendments to the Claims:









This listing of claims replaces all prior versions, and listings, of claims in the captioned application.


Listing of Claims:

- 1.-20 (cancelled)
21. (Previously presented) A product containing (a) a compound as defined in claim 25, and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HIV infection.
22. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 25 and (b) another antiretroviral compound.
23. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in claim 25.
24. (currently amended) A process for preparing a pharmaceutical composition ~~according to claim 23~~ comprising mixing a therapeutically effective amount of a compound as claimed in claim 25 ~~intimately mixed~~ with a pharmaceutically acceptable carrier.


25. (previously presented) A compound selected from the group consisting of:









;




;




;



;




;



;


or a pharmaceutically acceptable addition salt, or stereochemically isomeric forms thereof.

Claim 26. (previously presented) A compound of formula



or a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof, wherein

A and B each represents a radical of formula



ring E represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;

ring F represents phenyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl;

R¹ represents hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxy carbonyl;

C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl,

C₁₋₆alkyloxy carbonyl, C₁₋₆alkylcarbonyloxy; or C₁₋₆alkoxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxy carbonyl;

R² represents cyano; C₁₋₆alkyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or C₂₋₆alkynyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

X₁ represents -NR⁵-; -NH-NH-; -N=N-; -O-; -C(=O)-; -C₁₋₄alkanediyl-; -CHOH-; -S-;

-S(=O)_p-; -X₂-C₁₋₄alkanediyl-; -C₁₋₄alkanediyl-X₂-; or

-C₁₋₄alkanediyl-X₂-C₁₋₄alkanediyl-;

X₂ represents -NR⁵-; -NH-NH-; -N=N-; -O-; -C(=O)-; -CHOH-; -S-; or -S(=O)_p-;

m represents an integer of value 1, 2, 3 or 4;

R³ represents cyano; aminocarbonyl; amino; halo; NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³;

-C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; C₁₋₆alkyl optionally substituted with one or more substituents each independently selected from R^{3a};

C₁₋₆alkyloxy optionally substituted with one or more substituents each independently

selected from R^{3a}; C₁₋₆alkoxyC₁₋₆alkyl optionally substituted with one or more

substituents each independently selected from R^{3a} ; C_{2-6} alkenyl optionally substituted with one or more substituents each independently selected from R^{3a} ; C_{2-6} alkynyl optionally substituted with one or more substituents each independently selected from R^{3a} ; $-C(=N-O-R^8)-C_{1-4}$ alkyl; R^7 or $-X_3-R^7$;

R^{3a} represents halo, cyano, hydroxy, NR^9R^{10} , $-C(=O)-NR^9R^{10}$, $-C(=O)-C_{1-6}$ alkyl, $-C(=O)-O-C_{1-6}$ alkyl, $-C(=O)-polyhaloC_{1-6}$ alkyl, $-C(=O)-O-polyhaloC_{1-6}$ alkyl or R^7 ;

X_3 represents $-NR^5$; $-NH-NH-$; $-N=N-$; $-O-$; $-C(=O)-$; $-S-$; $-S(=O)_p-$;

$-X_{4a}-C_{1-4}$ alkanediyl; $-C_{1-4}$ alkanediyl- X_{4b} ; $-C_{1-4}$ alkanediyl- $X_{4a}-C_{1-4}$ alkanediyl; or $-C(=N-OR^8)-C_{1-4}$ alkanediyl;

X_{4a} represents $-NR^5$; $-NH-NH-$; $-N=N-$; $-C(=O)-$; $-S-$; or $-S(=O)_p-$;

X_{4b} represents $-NH-NH-$; $-N=N-$; $-O-$; $-C(=O)-$; $-S-$; or $-S(=O)_p-$;

each R^4 independently represents hydroxy; halo; C_{1-6} alkyl optionally substituted with one or more substituents each independently selected from R^{4a} ; C_{2-6} alkenyl optionally substituted with one or more substituents each independently selected from R^{4a} ; C_{2-6} alkynyl optionally substituted with one or more substituents each independently selected from R^{4a} ; C_{3-7} cycloalkyl; C_{1-6} alkyloxy; C_{1-6} alkyloxycarbonyl; C_{1-6} alkylcarbonyloxy; carboxyl; formyl; cyano; nitro; amino; mono- or di(C_{1-6} alkyl)amino; polyhalo C_{1-6} alkyl; polyhalo C_{1-6} alkyloxy; polyhalo C_{1-6} alkylthio; $-S(=O)_pR^6$; $-NH-S(=O)_pR^6$; $-C(=O)R^6$; $-NHC(=O)H$; $-C(=O)NHNH_2$; $NHC(=O)R^6$; $C(=NH)R^6$; or R^7 ;

R^{4a} represents halo, cyano, NR^9R^{10} , hydroxy or $-C(=O)R^6$;

R^5 represents hydrogen; aryl; formyl; C_{1-6} alkylcarbonyl; C_{1-6} alkyloxycarbonyl; C_{1-6} alkyl optionally substituted with formyl, C_{1-6} alkylcarbonyl, C_{1-6} alkyloxycarbonyl or C_{1-6} alkylcarbonyloxy; or C_{1-6} alkyloxy C_{1-6} alkylcarbonyl substituted with C_{1-6} alkyloxycarbonyl;

R^6 represents C_{1-6} alkyl, amino, mono- or di(C_{1-4} alkyl)amino or polyhalo C_{1-4} alkyl;

R^7 represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic,

bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may, whenever possible, optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxy carbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸), R^{7a}, -X₃-R^{7a} or R^{7a}-C₁₋₄alkanediyl-;

R^{7a} represents a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; or a monocyclic, bicyclic or tricyclic aromatic heterocycle; wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxy carbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O-R⁸);

R⁸ represents hydrogen, C₁₋₄alkyl optionally substituted with aryl, or aryl;

R⁹ and R¹⁰ each independently represent hydrogen; hydroxy; C₁₋₆alkyl; C₁₋₆alkyloxy; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxy carbonyl; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁₋₆alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxy carbonyl, cyano, amino, imino, mono- or di(C₁₋₄alkyl)amino, polyhaloC₁₋₄alkyl, polyhaloC₁₋₄alkyloxy, polyhaloC₁₋₄alkylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, or R⁷; or

R⁹ and R¹⁰ may be taken together to form a bivalent radical of formula

-CH₂-CH₂-CH₂-CH₂- (d-1);
-CH₂-CH₂-CH₂-CH₂-CH₂- (d-2);
-CH₂-CH₂-O-CH₂-CH₂- (d-3);
-CH₂-CH₂-S-CH₂-CH₂- (d-4);
-CH₂-CH₂-NR¹²-CH₂-CH₂- (d-5); or
-CH₂-CH=CH-CH₂- (d-6);

R¹¹ represents cyano; C₁₋₄alkyl optionally substituted with C₁₋₄alkyloxy, cyano, amino, mono- or di(C₁₋₄alkyl)amino or aminocarbonyl; C₁₋₄alkylcarbonyl;

C₁₋₄alkyloxy carbonyl; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹² represents hydrogen or C₁₋₄alkyl;

R¹³ and R¹⁴ each independently represent C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹⁵ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹⁶ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or R⁷;

-C-D- represents a bivalent radical of formula

-N=CH-NR¹⁷- (c-1); or
-NR¹⁷-CH=N- (c-2);


R¹⁷ represents hydrogen; C₁₋₆alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₄alkyloxy carbonyl or aryl;

p represents an integer of value 1 or 2;

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxy carbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, R⁷ or -X₃-R⁷;

provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a).


27. (Previously presented) A compound according to claim 26 wherein the compound has the formula



or a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof,

wherein R¹, R², R³, R⁴, ring E, ring F, C, D, X₁ and m are as defined in claim 26.


28. (Previously presented) A compound according to claim 27 wherein the compound of formula (I-A) has the formula



or a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof,

wherein R¹, R², R³, R⁴, ring E, ring F, C, D and X₁ are as defined in claim 26.


29. (Previously presented) A compound according to claim 26 wherein the compound has the formula



or a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof,

wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C, D, X_1 and m are as defined in claim 26.

30. (Previously presented) A compound according to claim 29 wherein the compound of formula (I-B) has the formula




or a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof,

wherein R^1 , R^2 , R^3 , R^4 , ring E, ring F, C, D and X_1 are as defined in claim 26.

31. (Previously Presented) A compound according to claim 26 wherein ring E is phenyl.

32 (Previously Presented) A compound according to claim 26 wherein ring F is phenyl.

33. (Previously presented) A compound according to claim 26 wherein the compound has the formula



or a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof, wherein

$-a^1=a^2-C(R^2)=a^3-a^4=$ represents a bivalent radical of formula

$$-\text{CH}=\text{CH}-\text{C}(\text{R}^2)=\text{CH}-\text{CH}= \quad (\text{a-1});$$
$$-\text{N}=\text{CH}-\text{C}(\text{R}^2)=\text{CH}-\text{CH}= \quad (\text{a-2});$$
$$-\text{CH}=\text{N}-\text{C}(\text{R}^2)=\text{CH}-\text{CH}= \quad (\text{a-3});$$
$$-\text{N}=\text{CH}-\text{C}(\text{R}^2)=\text{N}-\text{CH}= \quad (\text{a-4});$$
$$-\text{N}=\text{CH}-\text{C}(\text{R}^2)=\text{CH}-\text{N}= \quad (\text{a-5});$$
$$-\text{CH}=\text{N}-\text{C}(\text{R}^2)=\text{N}-\text{CH}= \quad (\text{a-6}); \text{ or}$$
$$-\text{N}=\text{N}-\text{C}(\text{R}^2)=\text{CH}-\text{CH}= \quad (\text{a-7});$$

$-b^1=b^2-b^3=b^4$ - represents a bivalent radical of formula

$$-\text{CH}=\text{CH}-\text{CH}=\text{CH}- \quad (\text{b-1});$$

-N=CH-CH=CH- (b-2);

$$-\text{N}=\text{CH}-\text{N}=\text{CH}- \quad (\text{b-3});$$

-N=CH-CH=N- (b-4); or

-N=N-CH=CH- (b-5);

-C-D- represents a bivalent radical of formula

$$-\text{N}=\text{CH}-\text{NR}^{17}- \quad (\text{c-1}); \text{ or}$$
$$-\text{NR}^{17}-\text{CH}=\text{N}- \quad (\text{c-2});$$

m represents an integer of value 1, 2, 3 and in case $-b^1=b^2=b^3=b^4$ is (b-1), then m may also be 4;

R¹ represents hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxy carbonyl; C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxy carbonyl, C₁₋₆alkylcarbonyloxy; or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxy carbonyl;

R² represents cyano; C₁₋₆alkyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or C₂₋₆alkynyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

X₁ represents -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, C₁₋₄alkanediyl, -CHOH-, -S-, -S(=O)_p-, -X₂-C₁₋₄alkanediyl- or -C₁₋₄alkanediyl-X₂-;

X₂ represents -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -CHOH-, -S-, -S(=O)_p-;

R³ represents NHR¹³; NR¹³R¹⁴; -C(=O)-NHR¹³; -C(=O)-NR¹³R¹⁴; -C(=O)-R¹⁵; -CH=N-NH-C(=O)-R¹⁶; cyano; halo; C₁₋₆alkyl; polyhaloC₁₋₆alkyl; C₁₋₆alkyl substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyl substituted with hydroxy and a second substituent selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxyC₁₋₆alkyl optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₁₋₆alkyloxy optionally substituted with one or more substituents each independently selected from cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkenyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; C₂₋₆alkynyl optionally substituted with one or more substituents each independently selected from halo, cyano, NR⁹R¹⁰, -C(=O)-NR⁹R¹⁰, -C(=O)-C₁₋₆alkyl or R⁷; -C(=N-OR⁸)-C₁₋₄alkyl; R⁷ or -X₃-R⁷;

X₃ is -NR⁵-, -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-, -X_{4b}-C₁₋₄alkanediyl-, -C₁₋₄alkanediyl-X_{4a}-, -C₁₋₄alkanediyl-X_{4b}-C₁₋₄alkanediyl-, -C(=N-OR⁸)-C₁₋₄alkanediyl-;

with X_{4a} being -NH-NH-, -N=N-, -O-, -C(=O)-, -S-, -S(=O)_p-; and

with X_{4b} being -NH-NH-, -N=N-, -C(=O)-, -S-, -S(=O)_p-;

each R^4 independently represents halo, hydroxy, C₁₋₆alkyl, C₃₋₇cycloalkyl,

C₁₋₆alkyloxy, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, mono- or di(C₁₋₄alkyl)aminocarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonyl, formyl, amino, mono- or di(C₁₋₄alkyl)amino or R^7 ;

R^5 is hydrogen; aryl; formyl; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxycarbonyl; C₁₋₆alkyl optionally substituted with formyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl or C₁₋₆alkylcarbonyloxy; or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl substituted with C₁₋₆alkyloxycarbonyl;

R^6 is C₁₋₄alkyl, amino, mono- or di(C₁₋₄alkyl)amino or polyhaloC₁₋₄alkyl;

R^7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted where possible with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, -CH(=N-O- R^8), R^{7a} , -X₃- R^{7a} or R^{7a} -C₁₋₄alkanediyl-;

R^{7a} is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted where possible with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, formyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, or -CH(=N-O- R^8);

R⁸ is hydrogen, C₁₋₄alkyl optionally substituted with aryl, or aryl;

R⁹ and R¹⁰ each independently are hydrogen; C₁₋₆alkyl; C₁₋₆alkylcarbonyl;

C₁₋₆alkyloxy; amino; mono- or di(C₁₋₆alkyl)amino; mono- or di(C₁₋₆alkyl)aminocarbonyl; -CH(=NR¹¹) or R⁷, wherein each of the aforementioned C₁₋₆alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, carboxyl, C₁₋₆alkyloxy, cyano, amino, imino, mono- or di(C₁₋₄alkyl)amino, polyhaloC₁₋₄alkyl, polyhaloC₁₋₄alkyloxy, polyhaloC₁₋₄alkylthio, -S(=O)_pR⁶, -NH-S(=O)_pR⁶, -C(=O)R⁶, -NHC(=O)H, -C(=O)NHNH₂, -NHC(=O)R⁶, -C(=NH)R⁶, R⁷; or

R⁹ and R¹⁰ may be taken together to form a bivalent radical of formula

-CH₂-CH₂-CH₂-CH₂- (d-1);

-CH₂-CH₂-CH₂-CH₂-CH₂- (d-2);

-CH₂-CH₂-O-CH₂-CH₂- (d-3);

-CH₂-CH₂-S-CH₂-CH₂- (d-4);

-CH₂-CH₂-NR¹²-CH₂-CH₂- (d-5); or

-CH₂-CH=CH-CH₂- (d-6);

R¹¹ represents cyano; C₁₋₄alkyl optionally substituted with C₁₋₄alkyloxy, cyano, amino, mono- or di(C₁₋₄alkyl)amino or aminocarbonyl; C₁₋₄alkylcarbonyl;

C₁₋₄alkyloxy; aminocarbonyl; mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹² represents hydrogen or C₁₋₄alkyl;

R¹³ and R¹⁴ each independently represent C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkenyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; C₂₋₆alkynyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹⁵ represents C₁₋₆alkyl substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl;

R¹⁶ represents C₁₋₆alkyl optionally substituted with cyano, aminocarbonyl or mono- or di(C₁₋₄alkyl)aminocarbonyl; or R⁷;

R¹⁷ represents hydrogen; C₁₋₆alkyl; or C₁₋₆alkyl substituted with aryl;

p is 1 or 2;

aryl represents phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl, mono or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₃₋₇cycloalkyl, C₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylthio, cyano, nitro, polyhaloC₁₋₆alkyl, polyhaloC₁₋₆alkyloxy, aminocarbonyl, R⁷ or -X₃-R⁷.

34. (Previously presented) A compound according to claim 26 wherein R² represents cyano.

35. (Previously presented) A compound according to claim 26 wherein R³ is cyano; aminocarbonyl; C₁₋₆alkyl optionally substituted with cyano or aminocarbonyl; C₁₋₆alkyloxy optionally substituted with cyano or aminocarbonyl; C₂₋₆alkenyl substituted with cyano or aminocarbonyl.

36. (previously presented) A compound according to claim 26 wherein m is 2; R¹ represents hydrogen; R² represents cyano; R³ represents cyano; C₁₋₆alkyl; C₁₋₆alkyl substituted with cyano; C₁₋₆alkyloxy optionally substituted with cyano; C₂₋₆alkenyl substituted with cyano or -C(=O)-NR⁹R¹⁰; each R⁴ independently represents halo, C₁₋₆alkyl or C₁₋₆alkyloxy; X₁ represents -NR⁵- or -O-; R⁵ represents hydrogen; R⁹ and R¹⁰ each independently are hydrogen or C₁₋₆alkyl; or R⁹ and R¹⁰ may be taken together to form a bivalent radical of formula -CH₂-CH₂-O-CH₂-CH₂- (d-3); R¹⁷ is hydrogen; C₁₋₆alkyl optionally substituted with hydroxy, cyano, aminocarbonyl, C₁₋₄alkyloxycarbonyl or aryl; aryl is phenyl substituted with C₁₋₆alkyloxy.

37. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 26.

38. (currently amended) A process for preparing a pharmaceutical composition ~~according to claim 37~~ comprising mixing a therapeutically effective amount of a compound of claim 26 with a pharmaceutically acceptable carrier.
39. (cancelled)
40. (Previously presented) A product containing (a) a compound as defined in claim 26 , and (b) another antiretroviral compound, as a combined preparation for simultaneous, separate or sequential use in the treatment of HIV infection.
41. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) a compound as defined in claim 26 , and (b) another antiretroviral compound.